Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimer’s Disease as Identified by Biomarkers

被引:0
|
作者
Thomas J. Montine
Elaine R. Peskind
Joseph F. Quinn
Angela M. Wilson
Kathleen S. Montine
Douglas Galasko
机构
[1] University of Washington,Department of Pathology
[2] University of Washington,Department of Psychiatry and Behavioral Sciences
[3] VA Puget Sound Health Care System,Mental Illness Research, Education, and Clinical Center
[4] Oregon Health and Science University and Portland VA Medical Center,Department of Neurology
[5] University of California at San Diego,Department of Neurosciences
来源
NeuroMolecular Medicine | 2011年 / 13卷
关键词
Alzheimer’s disease; Cerebrospinal fluid; Biomarkers; Aβ; Tau; F; -isoprostanes;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) is a common age-related chronic illness with latent, prodrome, and fully symptomatic dementia stages. Increased free radical injury to regions of brain is one feature of prodrome and dementia stages of AD; however, it also is associated with advancing age. This raises the possibility that age-related free radical injury to brain might be caused in part or in full by latent AD. We quantified free radical injury in the central nervous system with cerebrospinal fluid (CSF) F2-isoprostanes (IsoPs) in 421 clinically normal individuals and observed a significant increase over the adult human lifespan (P < 0.001). Using CSF amyloid (A) β42 and tau, we defined normality using results from 28 clinically normal individuals <50 years old, and then stratified 74 clinically normal subjects ≥60 years into those with CSF that had normal CSF Aβ42 and tau (n = 37); abnormal CSF Aβ42 and tau, the biomarker signature of AD (n = 24); decreased Aβ42 only (n = 4); or increased tau only (n = 9). Increased CSF F2-IsoPs were present in clinically normal subjects with the biomarker signature of AD (P < 0.05) and those subjects with increased CSF tau (P < 0.001). Finally, we analyzed the relationship between age and CSF F2-IsoPs for those clinically normal adults with normal CSF (n = 37) and those with abnormal CSF Aβ42 and/or tau (n = 37); only those with normal CSF demonstrated a significant increase with age (P < 0.01). These results show that CSF F2-IsoPs increased across the human lifespan and that this age-related increase in free radical injury to brain persisted after culling those with laboratory evidence of latent AD.
引用
收藏
页码:37 / 43
页数:6
相关论文
共 50 条
  • [31] Cerebrospinal fluid and blood biomarkers in Alzheimer's disease
    Humpel, Christian
    Hochstrasser, Tanja
    WORLD JOURNAL OF PSYCHIATRY, 2011, 1 (01): : 8 - 18
  • [32] Imaging and Cerebrospinal Fluid Biomarkers in the Search for Alzheimer's Disease Mechanisms
    Osorio, R. S.
    Pirraglia, E.
    Gumb, T.
    Mantua, J.
    Ayappa, I.
    Williams, S.
    Mosconi, L.
    Glodzik, L.
    de Leon, M. J.
    NEURODEGENERATIVE DISEASES, 2014, 13 (2-3) : 163 - 165
  • [33] Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease
    Mila-Aloma, Marta
    Suarez-Calvet, Marc
    Luis Molinuevo, Jose
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2019, 12
  • [34] Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum
    Lee, Jongmin
    Jang, Hyemin
    Kang, Sung Hoon
    Kim, Jaeho
    Kim, Ji Sun
    Kim, Jun Pyo
    Kim, Hee Jin
    Seo, Sang Won
    Na, Duk L.
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2020, 35 (44)
  • [35] Advances in the detection of Alzheimer's disease -: use of cerebrospinal fluid biomarkers
    Sjögren, M
    Andreasen, N
    Blennow, K
    CLINICA CHIMICA ACTA, 2003, 332 (1-2) : 1 - 10
  • [36] Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
    Leuzy, Antoine
    Cullen, Nicholas C.
    Mattsson-Carlgren, Niklas
    Hansson, Oskar
    CURRENT OPINION IN NEUROLOGY, 2021, 34 (02) : 266 - 274
  • [37] Brain Ventricular Volume and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
    Ott, Brian R.
    Cohen, Ronald A.
    Gongvatana, Assawin
    Okonkwo, Ozioma C.
    Johanson, Conrad E.
    Stopa, Edward G.
    Donahue, John E.
    Silverberg, Gerald D.
    JOURNAL OF ALZHEIMERS DISEASE, 2010, 20 (02) : 647 - 657
  • [38] Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers
    Mattsson, Niklas
    Andreasson, Ulf
    Carrillo, Maria C.
    Persson, Staffan
    Shaw, Leslie M.
    Zegers, Ingrid
    Zetterberg, Henrik
    Blennow, Kaj
    BIOMARKERS IN MEDICINE, 2012, 6 (04) : 401 - 407
  • [39] Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer's disease
    Zhang, Liding
    Liang, Xiaohan
    Zhang, Zhihong
    Luo, Haiming
    JOURNAL OF INNOVATIVE OPTICAL HEALTH SCIENCES, 2022, 15 (01)
  • [40] Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid
    Wiedrick, Jack T.
    Phillips, Jay, I
    Lusardi, Theresa A.
    McFarland, Trevor J.
    Lind, Babett
    Sandau, Ursula S.
    Harrington, Christina A.
    Lapidus, Jodi A.
    Galasko, Douglas R.
    Quinn, Joseph F.
    Saugstad, Julie A.
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 67 (03) : 875 - 891